[Guideline for the diagnosis and treatment of psoriasis arthropathica (psoriatic arthritis) in China (2026 edition)].

Psoriasis arthropathica, also known as psoriatic arthritis (PsA), is a highly heterogeneous systemic inflammatory disease. In addition to involving the skin with characteristic psoriatic lesions such as erythematous scaly plaques, it may also affect the joints, leading to joint pain, swelling, stiffness, and functional impairment, thereby substantially reducing patients' quality of life. To develop clinical practice guidelines that align with international standards for guideline development while reflecting Chinese clinical practice, the China Dermatologist Association, in collaboration with the Chinese Dermatovenerology Society of Integrative Medicine, initiated a guideline project focusing on 14 key clinical questions in the diagnosis and management of PsA in China. Evidence-based recommendations were formulated accordingly. This guideline systematically reviews recent domestic and international advances in the diagnosis and treatment of PsA, and covers diagnosis, disease activity assessment, therapeutic strategies, comorbidity management, and pharmacotherapy in special populations. The guideline aims to improve the overall standard of PsA diagnosis and management in China and ultimately enhance patient outcomes.